160 results about "Immune escape" patented technology

The invention discloses a preparation method of a human skin stem cell factor nano-liposome-exosome complex. According to the method, the exosome and the liposome are compounded, and through the synergistic effect between the exosome and the nano-liposome coated with the cytokine, the obtained compound system has good biocompatibility and immune escape performance, is free of cytotoxicity, not prone to being degraded by macrophages, good in stability and capable of continuously playing a role in vivo.

The invention relates to a preparation method of a cytotoxic T lymphocyte (CTL) targeting to multiple KRAS mutant antigen epitopes. The method comprises the steps: cloning a new artificial antigen coding sequence formed by series combination of 7 main KRAS mutant antigen epitope sequences into a lentivirus expression vector, transfecting DC, stimulating the proliferation and differentiation of activated CD8+T cells, and making the finally prepared cytotoxic T lymphocyte (CTL) having the specificity of targeting to seven main KRAS mutant antigen epitopes. The prepared KRAS mutant antigen specific cytotoxic T lymphocyte (CTL) has the advantages of high targeting specificity, no side effects and not easily causing of immune escape, and has great application prospects in treatment of KRAS mutant tumors.

The invention belongs to the field of tumour basic research, and relates to a method used separating and purifying microglia cells from glioma specimens. The method comprises following steps: a cell suspension is prepared from tumour tissues via mechanical method combined with enzymatic digestion method; the cell suspension is subjected to density gradient centrifugation so as to obtain the microglia cells of CD11B+ with a relatively high purity via enrichment and selection; and the microglia cells with a relatively high purity are obtained via further separation using CD11B+ magnetic beads. Wherein, Percoll separating medium is composed of 70% of Percoll, 30% of Percoll, and HBSS. The purity of the microglia cells obtained via percoll density gradient centrifugation enrichment can be more than 95%, and it is confirmed by immunofluorescence assay and phagocytosis assay that functions of the microglia cells are excellent. The method is simple and convenient for operation, is low in cost, is stable in quality, and is capable of providing basis for further research on immunologic functions microglia cells in brain glioma and effects of microglia cells in immune escape of tumour.

The invention provides a chimeric antigen receptor T cell and application thereof. The chimeric antigen receptor T cell expresses chimeric antigen receptors targeting CD19 and PD-L1 at the same time.The chimeric antigen receptor T cell expresses a CD19 CAR structure and a PD-L1 CAR structure at the same time, and after PD-L1 CAR is combined with PD-L1 expressed by a tumor cell, an activation signal can be transmitted intracellularly. Therefore, the chimeric antigen receptor T cell not only can recognize the tumor cells expressing CD19 in a targeted manner, but also can relieve immunosuppression of PD-1 expressed by the tumor cells on the T cells, avoid an immune escape mechanism of the tumor cells and relieve the problem of drug resistance of CAR-T treatment; and a new idea is provided for CAR-T treatment and adoptive feedback immune cell treatment.

The invention belongs to the field of tumor biological products, in particular to a chimeric antigen receptor and its gene and a recombinant expression vector, CD19-CD20 dual targeting T cells and anapplication thereof. The chimeric antigen receptor is CD20ScFv-L-CD19ScFv-CD8-CD137-CD3 zeta, which includes CD20ScFv, ligation peptide L, CD19ScFv, a hinge region and a transmembrane region of CD8, an intracellular signal domain of CD137, and an intracellular signal domain of CD3 zeta which are connected in series in order. In the treatment of B cell line hematological malignancy, the chimeric antigen receptor-modified T cells of the present invention can not only specifically recognize tumor cells expressed by a single target of CD19 antigen or CD20 antigen, but also to recognize tumor cellsco-expressed by two targets of CD19 antigen and CD20 antigen, compared with single target CAR T, dual-target CAR T has stronger anti-tumor activity, which avoids immune escape of tumor cells with lowabundance antigen expression, and the risk of recurrence is reduced.

The invention discloses a erythrocyte membrane-encapsulated rapamycin nanoparticles. The nanoparticles comprise a rapamycin nano-drug core, and the nano-drug core takes PLGA as a carrier and is encapsulated in an erythrocyte membrane. The nanoparticles disclosed by the invention cooperate with an efficient drug solubilizing effect and an autologous RBC nano-surface immune escape effect of an artificial nano-drug carrier; long-acting blood circulation can be shown, targeted atherosclerosis drug delivery and local controllable drug functionalization are achieved; plaque development is remarkablyimproved; and the effect of safely and efficiently treating atherosclerosis is achieved.

The invention relates to the construction of targeted NK cells used for tumor immunotherapy, and specifically relates to a preparation method for a membrane surface engineered NK cell, a pharmaceutical composition and an application. A targeting vector is adopted to introduce an azide group or DBCO on the surface of a NK cell, and polypeptide targeting PD-L1 can be coupled to the surface of the NKcell through copper-free click chemical reaction, so that a membrane surface engineered NK cell can be constructed. An application of the membrane surface engineered NK cell in treating PD-L1 positive tumor including head and neck squamous cell carcinoma, non-small cell lung cancer and triple negative breast cancer is also disclosed. Compared with the prior art, the preparation method has the following advantages: the targeting of the NK cell can be strengthened, so that potential hazards caused by viral vector transfection can be eliminated; the problems of CAR-T cell individualization and complex manufacturing processes can be solved; and the tumor infiltration capabilities and targeted killing activity of the NK cell can be enhanced, and immune escape mediated by a PD-1/PD-L1 pathway can be effectively blocked, so that the membrane surface engineered NK cell has potential clinical application prospets.

The invention discloses culturing, screening and amplifying techniques for hair follicle stem cells for clinic treatment level cell therapy. The bottlenecks are always research hotspots and difficulties in the biological stem cell field; currently, by carrying out separation and purification by virtue of remarkable adhering properties of a basement membrane, the hair follicle stem cells are obtained by virtue of three-dimensional culture and amplification measures. By depending on amplification anchorage-dependent cells, a three-dimensional high-simulation in-vivo extracellular matrix system is provided for screening and separating the levels of target cells. The method is a novel culture technique for culture in vitro of biological cells of stem cells of adults (embryo skin) in a high-simulation in-vivo adhesion environment. Skin seed hair follicle cells of targeted tissue engineering cultured through adhesion screening in the environment of a high-simulation substrate have high abdication capacity and multiplication capacity and can form a differentiated cortex structure in vitro. By screening immunogenic cells, immune escape is safely achieved, the transplant time is prolonged, the clinic application of tissue engineering is increased, the healing of wounds is promoted, and a solution with absolute advantages for the clinic treatment level cell therapy is provided for diseases of skin.

The invention discloses a nano photothermal therapy drug and a preparation method thereof. The nano photothermal therapy drug is composed of a nano-drug particle inner core and an outer cancer cell membrane, wherein the nano-drug system is composed of a heat shock protein inhibitor and polydopamine. The medicine can play roles in cancer cell membrane immune escape and tumor site self-targeting, photothermal therapy of polydopamine and sensitization low-temperature photothermal therapy of a heat shock protein inhibitor, carry out strike therapy for the thermal resistance of tumor cells, quicklyrelease the heat shock protein inhibitor and reduce the hepatotoxicity of the heat shock protein inhibitor, has excellent photothermal imaging and fluorescence imaging characteristics, and can be used for cancer targeted imaging and phototherapy; and high-accumulation and low-dose HI formed at self-targeting tumor sites can achieve an ideal effect, and possible toxicity to healthy organs due to excessive use is avoided.

Provided is a use of miRNA-214 inhibitor in inhibiting regulatory T cells (Treg cells). The microRNA-214 (miRNA-214) can promote Treg cells, and can assist tumours in immune escape. The experiments demonstrate that the inhibition of miRNA-214 can inhibit the growth of Treg cells, thus inhibiting the growth of tumours. Therefore, miRNA-214 can be used for developing an anti-tumour drug or a drug inhibiting immune response hyperactivity.

The invention discloses a scoring method for quantifying a TIME infiltration mode; the score for quantifying the TIME infiltration mode is called as a TIME index (TI), the TI is an excellent prognosisprediction index in hepatocellular carcinoma and pancreas carcinoma, and the performance of the TI in predicting immunotherapy response is superior to that of other 11 biomarkers. The results can strengthen the understanding of the immune microenvironment and guide more effective personalized treatment, and the TIME1 is characterized by immune cell depletion and cell proliferation and correspondsto immunodeficiency types; tIME2 is characterized by being in an immunosuppression state, and a potential immune escape mechanism of each phenotype is emphasized corresponding to immunosuppression: TIME1 is characterized by tumor infiltration leukocyte deficiency and tumor antigen presentation capability defects; the TIME2 has more immunosuppressive cells; the TIME3 is rich in immunosuppressive cytokines and immune checkpoint molecules.